What nine Latin American regulators actually require for translating preclinical dossiers

For a decade, sponsors and CROs filing preclinical dossiers in Latin America have operated on two inherited assumptions. Both are, in the primary regulatory texts, largely wrong for preclinical content — and they compound, because paying to solve the wrong problem twice is how a $500 translation invoice becomes a $50,000 one.

Assumption 1 — Sworn, page-for-page

The first assumption is that every preclinical document must be fully translated into Spanish (or Portuguese for Brazil) by a sworn translator, with every table recreated, every figure relabeled, and the source layout mirrored page for page. That is the "translate everything, sworn, page-for-page" default. Read against the primary instruments, this is wrong on two axes simultaneously — the translator tier and the visual replication requirement — as this article documents.

Assumption 2 — Translate the whole corpus, not just the summary

The second assumption is quieter and more expensive: that regulators demand the entire preclinical body of evidence be translated. A single GLP toxicology program can run 300, 500, 700 pages; a full nonclinical package for a novel drug or device is routinely in the low thousands. The industry has been quoting and paying to translate all of it. Several LATAM regulators — Colombia (INVIMA) for devices, Peru (DIGEMID) for drug Modules 3, 4 and 5, Brazil (ANVISA) for both drug and device dossiers, Ecuador (ARCSA) for biologics — have written down, in operative instruments, that the compliant deliverable is the source English document preserved plus a substantive Spanish summary. The summary is a handful of pages. What gets translated is the substantive summary, not the corpus.

The economic delta between the two deliverables is roughly two orders of magnitude on a mid-size preclinical dossier. A 500-page GLP program translated in full at industry rates ($0.28–$0.45/word, roughly 275 words/page) is a $38,000–$62,000 invoice. The same program delivered as source English preserved plus a 10-page substantive Spanish summary at our Tier 1-B rate ($0.19–$0.24/word) is a $500–$700 invoice. That is a ~60–100x cost delta on a single document class, produced by correctly reading two circulars.

We pulled the primary regulations for nine regulators covering the entire commercial map of Latin America, read them against each other, and mapped what they actually say about translating preclinical test reports, GLP animal studies, biocompatibility, sterilization validations, mechanical and electrical bench tests, and CTD Module 4 non-clinical content. The pattern is not LATAM-specific — in our companion analysis of eight non-LATAM regulators (FDA, EMA, PMDA, NMPA, MHRA, Health Canada, TGA, Swissmedic), the same finding holds: no primary instrument requires visual replication of a Module 4 study report, and ICH's own M4 organisation guidance is silent on translation and layout altogether. The default that has cost the industry the most money for the longest time is a convention that no regulator, anywhere in the developed world, has written down.

Colombia is the only regulator in the survey that has written down, in an operative instrument, the exact concession that matters for table-heavy preclinical documents. INVIMA's Circular Externa 5000-0001-22 (August 2022), Section II.1 on translation of technical-scientific information, is worth quoting verbatim:

“En virtud de lo dispuesto en el artículo 49 y en los literales d, e, i, j, y k del artículo 18 del Decreto 4725 de 2005, los siguientes documentos completos se aceptarán en inglés acompañados con un resumen al idioma castellano”

The circular then enumerates the accepted documents: technical studies and analytical verifications, biocompatibility studies, sterility studies, stability studies, risk analyses, clinical studies, electrical safety test reports, and — critically for anyone shipping a report full of measurement tables — tables or matrices referencing technical information. It closes by stating that information contained in graphs or diagrams does not require translation.

The delivery model INVIMA endorsed is full English document plus Spanish summary. The tables stay in English. The figures and diagrams stay in English. What gets translated is the substantive summary.

One caveat. The Colombian carve-out is written into the device instrument. Its drug counterpart, Decreto 677/1995, has no equivalent Article 49, and the biologics instrument, Decreto 1782/2014, contains no language article. Drug and biologics filings need to be scoped separately. And Tier 1 legal documents still require an official translator certified by the Ministerio de Relaciones Exteriores, with apostille, as cumulative and non-waivable requirements.

Mexico — COFEPRIS requires Spanish, or an accompanying Spanish translation, for every dossier document. But Reglamento de Insumos para la Salud Article 153 draws the sworn/simple line by document origin, not subject matter: a perito traductor is required only for documents issued by foreign authorities. Everything else — including preclinical test reports and CTD Module 4 — can be submitted with a traducción simple endorsed by the responsable sanitario's signature. The DOF procedure catalogue confirms this across every drug and device homoclave.

Argentina — ANMAT has the strictest translator qualification in Latin America — traductor público matriculado registered with the Colegio de Traductores Públicos, plus Colegio legalization plus apostille — but the narrowest scope of application. In Disposición 727/2013 that clause appears at exactly five places, each for foreign legal or authority instruments. For the technical and preclinical dossier body, including authenticated copies of the complete test reports supporting essential safety and performance requirements, Article 3(e) requires only that the legal representative and technical director sign and declare. No translator clause is attached.

For clinical trials, the picture just shifted. Disposición 6677/2010 §2.4, which expressly exempted the Investigator's Brochure from the Spanish requirement, was repealed by Disposición 7516/2025, in force December 1, 2025. The new instrument contains no general Spanish rule at all; Spanish is mandated only for recruitment advertising, the investigational product label, and the principal investigator's CV. The express carve-out became an unspecified silence — materially the same outcome on a different textual basis. Confirm with ANMAT before treating an English-only IB as a compliant default.

Chile — ISP has no sworn-translator requirement and no general Spanish-language mandate for technical or preclinical dossier content. The Ministerio de Relaciones Exteriores translation service is expressly optional. The operative standard is Decreto Supremo 3/2010 Article 29 No. 10: legal documents in Spanish or duly translated under the signature of the legal representative, the professional assigned by the company, or the technical director. The formality attaches to the foreign document itself — notarization, apostille, consularization — not to the translation. ISP SDM/001 confirms that device test reports are accepted as valid documentation as-is. For clinical trials the peculiarity runs the opposite way: Resolución Exenta 5161/2016 requires the protocol and Investigator's Brochure in both English and Spanish, waived only for studies of national origin or from Spanish-speaking countries.

El Salvador — SRS is our closest home market — Amavita Sciences™ and bioaccess® file here regularly — and the picture is the conservative-silent pattern of Mexico plus a summary-level carve-out for preclinical. RTS 11.03.02:21 restricts Spanish to labels, instructions for use and used-equipment manuals; the pharma guide at §5 states everything must be in Spanish or accompanied by a translation, with the highest-formality translation reserved for legal documents and powers. Most importantly, the Central American technical regulation RTCA 11.03.59:18 §7.11.1 asks for concluding reports of preclinical studies, not the full underlying study reports.

Panama — DNFD is moving the opposite direction. For clinical studies, Decreto Ejecutivo 27/2024 Article 30 opens an express English route provided the filing is accompanied by a Spanish summary of all clinical evidence. But the draft medical-device decree circulating in the Cámara de Comercio, if promulgated as drafted, would require sealed sworn translations of foreign documents including catalogues, manuals and instructions for use, and official translation of IVD validation protocols including linearity, limit of detection and quantitation, and reproducibility tables. It is not in force as of publication. Monitor closely.